Mect Corporation

Mitsui Toatsu Chemicals, Incorporated

Rikagaku Kenkyusho

Masaaki Numata

Tomoya Ogawa

Mamoru Sugimoto

Masayoshi Ito

Yoshiyasu Shitori

Makoto Tanaka

Takayuki Ishii

Shoji Yoshimura

Kenkichi Tomita

Ryoichi Osawa

Shohei Shibayama

Isao Suda

Mariko Ishii

Nobuyuki Kibushi

Makiko Kasano

Tae Yasunaga

Naokazu Sugiyama

Shigeki Nunomura

Shuji Fujita

Akira Endo

Akira Awaya

Yoshitaka Nagai

Yusaku Ishizuka

Hisashi Kobayashi

Hayao Abe

Reiji Kannagi

Yoshiko Kirihata

Masanori Kobayashiu

Masami Iida

Masamichi Fujita

Lewis-associated compound, process for producing the same, and

An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts, thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.

Method for modulating the immune system

An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.

Methods for inhibiting the chemotaxis of neutrophils

Anti-inflammatory agent

GM.sub.3 analogous compound (I) below: ##STR1## wherein one of R.sup.2 and R.sup.3 represents a neuramic acid group represented by general formula (V): ##STR2## R.sup.5 represents ##STR3## or hydrogen; R.sup.6 represents hydrogen or a ceramide group represented by general formula (VI): ##STR4##

GM.sub.3 analogous compound

A monoclonal antibody A exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc.alpha.2.fwdarw.9NeuAc terminal. A monoclonal antibody B exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc.alpha.2.fwdarw.6Gal.beta. terminal. A monoclonal antibody C exhibits specificity to the sialic acid glycolipid containing at least one epitope selected from the group of NeuAc.alpha.2.fwdarw.9NeuAc terminal, NeuAc.alpha.2.fwdarw.6Gal.beta. terminal and NeuAc.alpha.2.fwdarw.1Cer. Hybridomas are prepared which produce antibodies A, B and C. A process for producing the hybridomas is disclosed including the step of fusing a myeloma cell and a B cell (lymphocyte) produced by the immunization of animal using as an antigen, the sialic acid glycolipid containing at least one epitope of the group NeuAc.alpha.2.fwdarw.9NeuAc terminal, NeuAc.alpha.2.fwdarw.6Gal.beta. terminal and NeuAc.alpha.2.fwdarw.1Cer.

Monoclonal antibody recognizing un-natural ganglioside GD3

The present invention relates to ganglioside related compounds having, for example, the following formula: ##STR1## where R.sub.1 represents H or COCH.sub.3 (hereinafter abbreviated to 'AC'); R.sub.2 represents H or CH.sub.3 ; and R.sub.3 represents --OH, ##STR2## These ganglioside related compounds are useful as membrane receptors, tumor markers, cell growth controlling substances, etc., and useful for immunotherapy for cancer, etc.

Ganglioside related compounds and method of producing the same

The present invention relates to sialic acid derivatives. According to the present invention, there is provided sialic acid derivatives having the general formula (I): ##STR1## wherein, R.sup.1 represents hydrogen, an acetyl group, a trityl group, ##STR2## (R.sup.5 represents hydrogen or an acetyl group and R.sup.6 represents hydrogen, sodium or a methyl group). R.sup.2 represents hydrogen or an acetyl group,

Sialic acid derivatives and process therefor

A sialic acid-bonded octapeptide represented by the following general formula (I): ##STR1## wherein R represents a hydrogen atom or an acetyl group; and R' represents a lower alkyl group, an aralkyl group, a hydrogen atom or an alkali metal atom, is herein disclosed. The peptide chain of the sialic acid-bonded octapeptide is constituted by 8 amino acid molecules on the C-terminus side of FTS and the compounds represented by formula (I) can be obtained by bonding sialic acid to the amino terminus of the peptide chain according to condensation. These octapeptides show excellent physiological activity comparable to FTS and a half life in blood longer than that of FTS and it is expected that the affinity of the peptide to lymphocytes is also enhanced. Thus they can effectively be used as medicines for treating the lowering and abnormality of functions of the thymus.

Sialic acid-bonded octapeptide and preparation thereof

The present invention provides ganglioside-related compounds expressed by the following formula: ##STR1## (wherein R.sub.1 denotes a hydrogen atom or SiR.sub.3 R.sub.4 R.sub.5 (wherein R.sub.3 and R.sub.4 each denotes a methyl or phenyl group, and R.sub.5 denotes a tertiary butyl or dimethylphenylmethyl group), and R.sub.2 denotes a hydrogen atom, a trityl group, or ##STR2## (wherein M denotes an alkali metal atom)) and methods of producing the same. These ganglioside-related compounds are useful as markers for the early detection of cancer and in the immunotherapy for cancer.

Glycolipid containing N-glycolylneuraminic acid and method of producing

A sialic acid derivative having an active carbonyl group represented by the formula [I]: ##STR1## wherein R.sup.1 represents hydrogen or acetyl group; R.sup.2 represents hydrogen, a metal or a lower alkyl group; R.sup.3 represents hydrogen, hydroxyl group, or a residue removed hydrogen from an alcohol portion of an active ester; Ac represents acetyl group; and n is 1 to 20, respectively. This sialic acid derivative [I] can be utilized as a starting material for various complex having a sialic acid in the molecule since it has an active carbonyl group in the molecules so that it shows high reactivity.

Sialic acid derivatives having active carbonyl group

This invention provides a novel compound having a formula such as ##STR1## This invention also provides a process for preparing such a compound.

Sialosylcerebrosides

This invention provides a novel compound expressed by the following formula (1): ##STR1## [wherein R.sup.1 denotes a hydrogen atom or CH.sub.3 CO--, R.sup.2 denotes --COOR.sup.4 (R.sup.4 denotes Na or a methyl group) or ##STR2## (R.sup.5 denotes a hydrogen atom, --COC.sub.6 H.sub.5 or --Si(C.sub.6 H.sub.5).sub.2 C(CH.sub.3).sub.3 and R.sup.3 denotes ##STR3## (R.sup.5 denotes a hydrogen atom, --COC.sub.6 H.sub.5 or --Si(C.sub.6 H.sub.5).sub.2 C(CH.sub.3).sub.3) when R.sup.2 is --COOR.sup.4 (R.sup.4 denotes Na or a methyl group) or denotes --COOR.sup.4 when R.sup.2 is ##STR4## and a method of preparation thereof. The above novel compounds of present invention are useful as a tumor maker, a molecular marker for cells having the ability of differential induction, or an intermediate of the synthesis thereof. 'Y

Sialosylceramides and production method thereof

Growing community of inventors

Kawagoe, Japan

Masaaki Numata